Pitches · 8:00–9:30 AM PT
Amynas, Inc.
Lode Debrabandere, CEO · ldebrabandere@amynas.com
Infection-protection for a surgical implants, incl. pacemakers, Neuro-stimulatory devices and breast implants. Our technology includes NanoBiotics, a nanofiber electrospun envelope with embedded potent antibiotics capable to protect against deadly superbugs in hospitals
Round
$5 Million Convertible Note @ $15 Million
Closed
Just started. Nothing closed at this point in time
FDA milestone
Completed 4 FDA meetings with full clarity on FDA Testing Plan
FDA timeline
FDA 510(k) submission planned for end of 2027 -
Other groups in round
we just started but have one group that initiated DD
DD package
no.
Traction: Completed $4.7 Million seeding round and completed efficacy, long term safety and stability testing. Upgraded manufacturing plant.
What they're looking for: no
After the session
Investor sentiment
Medium interest
1
Low interest
5
No interest
16
22 responses
Investor engagement
2
Invitations to apply
Simergent
Steve Lindo, CEO · sjlindo@simergent.com
Simergent has developed a transformative FDA-cleared home dialysis device and consumables designed to drastically increase uptake and usability of home dialysis at 1/3 of the cost of traditional devices.
Round
5000000 Priced Round @ 15000000
Closed
2000000
FDA milestone
FDA 510(k) clearance achieved Oct 2025
FDA timeline
already cleared
Other groups in round
Dr. Harvey Family Office, Angel Physicians Fund, Velocious Investments, MTT Ventures, various nephrologists and cardiologists
DD package
yes
Traction: 4 LOIs from top-10 dialysis clinic networks, one free pilot agreement signed by Indiana University
What they're looking for: Advisors are always welcome who can help us transform from R&D to commercialization
After the session
Investor sentiment
High interest
1
Medium interest
9
Low interest
3
No interest
4
Will be interested at next round
1
18 responses
Investor engagement
3
Invitations to connect
6
Invitations to apply
Corit Medical
Aaron Tutwiler, CEO · aarontutwiler@coritmedical.com
Corit is a single-use, purely mechanical device for inferior turbinate reduction that helps ENT surgeons simplify one of their most common nasal airway procedures. It eliminates capital-intensive equipment, fits existing workflows, protects critical surrounding tissue, and allows controlled turbinate bone removal within an already reimbursed procedure.
Round
$800,000 Priced Round @ $10,000,000
Closed
$300,000
FDA milestone
FDA registered 2022, renewed annually as Class I, 510(k)-exempt device
FDA timeline
N/A
Other groups in round
K2X, Keiretsu MST, VIPC, AVP
DD package
Yes
Traction: FDA registered, reimbursed procedure, IP secured, and over 300 real-world procedures completed
What they're looking for: ENT surgeon KOLs and customer introductions are welcome
After the session
Investor sentiment
High interest
1
Medium interest
1
Low interest
7
No interest
7
16 responses
Investor engagement
1
Invitations to connect
1
Invitations to apply